JBF Capital, Inc.
Q3 2025 13F-HR/A Holdings
Net value change ($000)
+77,951
(12.4%)
New positions
21
Sold out positions
8
Turnover %
4.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| VOO | 22,580 | 7.8% |
| GOOGL | 20,257 | 499.8% |
| META | 7,268 | 48.0% |
| GRBK | 4,793 | 17.5% |
| MSFT | 3,677 | 4.1% |
| ATMP | 3,581 | NEW |
| Theratechnologies Inc. | 2,884 | NEW |
| QQQ | 2,242 | 8.8% |
| XBI | 1,503 | NEW |
| URI | 1,409 | 26.7% |
Top Reduces (Value $000, Stocks/ETFs)
| IBIT | -5,325 | -100.0% |
| VST | -4,845 | -100.0% |
| NFLX | -1,108 | -10.5% |
| ICAD INC | -686 | -100.0% |
| Vigil Neuroscience, Inc. | -557 | -100.0% |
| NOW | -345 | -10.5% |
| INBX | -299 | -100.0% |
| BHVN | -186 | -100.0% |
| CRWD | -180 | -3.7% |
| Akoya Biosciences, Inc. | -155 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,136
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|